α_IIbβ₃-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells

Title:α_IIbβ₃-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells

Volume: 16 Issue: 13

Author(s): Joanna Kononczuk, Arkadiusz Surazynski, Urszula Czyzewska, Izabela Prokop, Michal Tomczyk, Jerzy Palka and Wojciech Miltyk

Affiliation:

Keywords: α_IIbβ₃-integrins, α_IIbβ₃-inhibitors, abciximab, eptifibatide, MCF-7 breast cancer cells, apoptosis.

Abstract: Integrin receptors are considered to be the key factors in carcinogenesis. α_IIbβ₃-Integrin (GP IIb/IIIa) is the main glycoprotein of the surface of platelets, its presence has also been noted on the certain cancer cell lines. The molecular mechanism of its action in cancer cells remains unknown. This study presents effects of two α_IIbβ₃-inhibitors: Abciximab and Eptifibatide on apoptosis, expression of proline oxidase (POX), signaling molecules ERK 1/2, transcription factor NF-κB and HIF-1α, vascular endothelial growth factor (VEGF) as well as DNA biosynthesis, collagen biosynthesis and prolidase activity in MCF-7 breast cancer cells. Both ligands induced apoptosis, however we found significant differences in molecular mechanism of action between tested α_IIbβ₃-inhibitors. These differences include expression of POX, HIF-1α, NF-κB,VEGF and collagen biosynthesis. Eptifibatide presented stronger proapoptotic activity in MCF-7 cells than Abciximab. Results of this study suggest that Eptifibatide may be considered as a novel candidate for development of new anticancer therapy.

Cite this article as:

Kononczuk Joanna, Surazynski Arkadiusz, Czyzewska Urszula, Prokop Izabela, Tomczyk Michal, Palka Jerzy and Miltyk Wojciech, α_IIbβ₃-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells, Current Drug Targets 2015; 16 (13) . https://dx.doi.org/10.2174/1389450115666140804220441